Filing Details
- Accession Number:
- 0001209191-18-002258
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-04 19:54:14
- Reporting Period:
- 2018-01-02
- Accepted Time:
- 2018-01-04 19:54:14
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1131324 | Genomic Health Inc | GHDX | Services-Medical Laboratories (8071) | 770552594 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1649689 | J James Vaughn | 301 Penobscot Drive Redwood City CA 94063 | Chief Commercial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2018-01-02 | 2,169 | $17.33 | 30,481 | No | 4 | M | Direct | |
Common Stock | Disposition | 2018-01-02 | 2,169 | $34.09 | 28,312 | No | 4 | S | Direct | |
Common Stock | Disposition | 2018-01-02 | 835 | $34.09 | 27,477 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2018-01-02 | 2,169 | $0.00 | 0 | $17.33 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2018-12-04 | No | 4 | M | Direct |
Footnotes
- Includes an aggregate of 17,374 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 8, 2017.
- Represents actual sale price.
- The option became exercisable as to 25% of the shares on December 4, 2009, and became exercisable as to 1/48th of the shares each full month thereafter.